Therapeutic Effect of Nebulized Hypertonic Saline for Muco-Obstructive Lung Diseases: A Systematic Review and Meta-Analysis with Trial Sequential Analysis
- 1 March 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 69 (3), 742-748
- https://doi.org/10.1136/jim-2020-001479
Abstract
Overproduction of mucus and impaired clearance play important roles in the pathogenesis of muco-obstructive lung diseases (MOLDs). This study aims to evaluate the therapeutic effect and safety of nebulized hypertonic saline (HS) on MOLDs. Five electronic databases including PubMed, Excerpt Medica Database (EMBASE), Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and International Standard Randomized Controlled Trial Number Register were searched until June 2019. Randomized controlled trials or randomized controlled crossover trials which investigated the therapeutic effect of HS versus non-HS for MOLDs were included. Twenty-one studies met the eligibility criteria. For cystic fibrosis (CF), although the forced expiratory volume in the first second and forced vital capacity did not improve significantly (mean difference (MD) −0.48, 95% CI −3.72 to 2.76), (MD 1.85, 95% CI −4.31 to 8.01), respectively), the clearance capability of lung and quality of life (QOL) improved significantly in the HS group ((standard mean difference 0.44, 95% CI 0.02 to 0.87), (MD −0.64, 95% CI −)1.14, to 0.13), respectively). However, the results of trial sequential analysis showed the evidence needed more researches to support. The effect of nebulized HS on non-CF bronchiectasis, chronic obstructive pulmonary disease, and primary ciliary dyskinesia also need more evidence to conclude, since current studies are limited and results are inconsistent. Most adverse events of nebulized HS were mild and transient. In summary, the current available evidence suggests that nebulized HS may increase the QOL in CF, but there was no significant improvement in lung function. However, it is not possible to draw firm conclusions for other MOLDs due to limited data.Keywords
This publication has 47 references indexed in Scilit:
- Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic FibrosisJAMA, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosisBMC Pulmonary Medicine, 2011
- Hypertonic saline or high volume normal saline for viral bronchiolitis: Mechanisms and rationalePediatric Pulmonology, 2009
- Rationale for Hypertonic Saline Therapy for Cystic Fibrosis Lung DiseaseSeminars in Respiratory and Critical Care Medicine, 2007
- Respiratory Tract Mucin Genes and Mucin Glycoproteins in Health and DiseasePhysiological Reviews, 2006
- Cystic FibrosisThe New England Journal of Medicine, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Inhaled hypertonic saline increases sputum expectoration in cystic fibrosisJournal of Paediatrics and Child Health, 1996